RE:RE:RE:RE:RE:Financials out last night Thanks for your comments on the financial reporting.It will be interesting to follow the financials going forward. After a significant uptick in revenue in the July 2022 quarter when the Abbvie deal was closed, the revenue level decreased the following quarters before the uptick in the latest April 2023 quarter to 59 thousand.
We know that the Abbvie deal will generate revenue in terms of sales of compound, milestones and royalties. I agree that sales of compound for 59 thousand is an indication of product manufacturing rather th an testing. It will be very interesting to follow the revenue figure going forward.
I don’t know how long it will take for Abbvie to come to the market with a product launch but most of the work is already done by Geraldines crew, right?
How about milestones and milestone payments, anyone?
Have worked in projects with milestones, but not in this industry, so really don’t know, but should a milestone payment not be made in conjunction with sales starting up?